Pharmaceuticals
60 recent notes from companies in this sector. 20 companies tracked.
Indoco cuts debt target, USFDA audit still open
Q1 EBITDA margin improved to 10.3% from 3.8%, but management lowered near-term debt repayment goal by ₹30 crore and gave no timeline for USFDA clearance.
Medplus sees another 4.08% of equity pledged; total with Catalyst tops 17%
Catalyst Trusteeship created a pledge over 4.9 million shares on June 24. The pledgor is unnamed while promoters already have 60.7% of their holding pledged.
Zenotech swings to ₹45.55 lakh net loss in Q1 on higher costs
Revenue from operations rises 11% but employee and other expenses push the nano-cap pharma company into the red, versus a profit of ₹98.96 lakh a year ago.
Zenotech posts ₹45.55 lakh net loss in Q1 as costs surge
Zenotech Laboratories swung to a net loss of ₹45.55 lakh in Q1 FY27 from a profit of ₹98.96 lakh a year earlier, as expenses outpaced revenue growth of 11%.
Pfizer Q2 profit up 6.6% to ₹204 cr, CFO gap lingers
Revenue rose 8.3% to ₹653 cr, with no exceptional charges lifting net profit. But the board meeting came a day after the CFO resigned, leaving a leadership hole.
Alembic gets USFDA OK for Prucalopride, but $100M market faces competition
The approval adds a chronic-constipation generic to Alembic’s US pipeline, but generic competition and the company's scale make the near-term financial impact negligible.
AstraZeneca India gets Enhertu nod for early-stage breast cancer
The drug regulator cleared neoadjuvant use in HER2-positive Stage II/III breast cancer, expanding the addressable pool for the company's top oncology product, which already drove over ₹22,756 mn in FY26 revenue.
Indoco's ₹97 cr sale masks core loss; auditor flags subsidiary's future
June-quarter profit of ₹65 cr is entirely from the ophthalmic division sale. Excluding it, operations are in the red. Auditor material uncertainty on FPP Holding adds another concern.
Indoco Q1 profit hinges on ₹97 cr ophthalmic sale gain
Standalone revenue up 6% to ₹408 cr, but pre-tax loss of ₹4.1 cr before exceptional items. EBITDA margin improves to 10.3% but core business under pressure.
Cipla wins US FDA nod for generic Advair Diskus
The approval opens a $908M asthma/COPD market, with launch in Q2 FY27. A single Form 483 observation at the New York facility adds a small caveat.
Anlon Healthcare to consider share swap for full control of two units
Board to meet July 30 to approve acquiring remaining 32.52% in Apiqo Organics and 43.33% in Bizotic LifeScience via preferential equity; no valuation disclosed.
Senores Pharma targets 50-60% PAT growth after Q1 beat
Revenue rose 36% to ₹180 cr, PAT up 56% to ₹31 cr. Management guided for full-year PAT growth of 50-60% and plans to commercialize 35 ANDAs over 18-20 months.
Oxygenta Pharma Q1 revenue surges 144%, loss narrows 66%
Revenue hits **₹37 cr** from **₹15 cr**; net loss shrinks to **₹2.1 cr**. AGM set for August 21.
Senores delays Atlanta plant, redirects ₹65 cr of IPO funds
The sterile injectables facility at Atlanta won't be ready until Q4 FY28; the company now plans to use freed-up cash for ANDA buys and existing site expansions.
Cipla posts ₹7,119 cr Q1 revenue, reiterates FY27 margin guidance
The transcript adds nothing new beyond the July 23 concall; numbers were already known. Key: India business grew 12%, US Ventolin launched, EBITDA margin target 18.5-20%.
Pfizer loses CFO Amit Agarwal; no successor named
Amit Agarwal resigns to pursue external opportunity, stays until Oct 8, 2026. No successor or disagreement disclosed, adding uncertainty for a mid-cap pharma with declining profits.
Bajaj Healthcare Q1 transcript tells no new story
The transcript of the July 21 earnings call, filed July 27, confirms the ₹166 cr revenue and ₹14 cr profit reported earlier. No surprises.
Senores Q1 revenue jumps 36% to ₹180 cr, profit up 56%
Regulated markets lead with 42% growth as ANDA portfolio expands to 58 products; EBITDA surges 87% to ₹54 crore.
Senores Q1 profit rises 56% on regulated markets growth
Revenue up 36% to ₹180.2 cr, EBITDA surges 87%. Results in line with guided trajectory.
Senores' Q1: Revenue up 36%, profit up 56% — in line with guidance
Strong growth but priced in. EBITDA margin expanded to nearly 30%. Anjali Shah appointed as senior management.
Senores Q1 profit surges 44% on regulated markets growth
Revenue climbs 36% to ₹180 crore, but the numbers were well telegraphed in guidance.
Granules India submits Q1 FY27 earnings transcript — no new material
A routine transcript filing adds nothing beyond what was discussed on the live July 21 call. The company's next catalysts are the LUMRYZ FTF and FDA observations.
Unick proposes H. M. Ravn as MD after Bhupen Vasa's death
The board will meet on July 31 to consider redesignating Whole-time Director H. M. Ravn as Managing Director, filling the gap from the sudden death of former MD Bhupen Navnit Vasa on June 4.
Mercury Labs net profit plunges 69% as revenue slips in Q1
Pharma nano-cap posts ₹29.78 lakh profit vs ₹96.76 lakh a year ago; revenue down 12% to ₹15.96 crore.
Mercury Labs profit dives 69% in Q1 as revenue slips 12%
Net profit plunges to ₹29.78 lakh from ₹96.76 lakh a year ago; auditors issue unmodified report.
Onesource reverses stance on DDC contracts, accelerates capacity
In Q1 FY27 concall, management reveals it is now accepting new manufacturing service agreements after prioritizing commercial sales, and pulls forward soft-gelatin fill timeline to 12-15 months.
MedPlus steps beyond pharmacy with ₹155 cr food-and-wellness bets
The pharmacy chain diversifies into cold-press oils and concierge health, but the ₹155 cr spend is just 1.7% of revenue.
Aurobindo's biosimilars arm clears Brazil's ANVISA for Hyderabad plant
The facility already held EMA and WHO certifications. The ANVISA nod opens the door to Latin America, but for a ₹33,653 cr giant it's an incremental step, not a game-changer.
Glenmark wins U.S. pediatric approval for RYALTRIS nasal spray
FDA expands label to children 6–12, broadening the allergy brand's addressable market. For a company with over ₹16,000 cr in annual sales, the near-term revenue lift is modest but the strategic fit is clear.
Lupin spins out two oncology assets into new company, takes 82% stake
Lupin's US unit licenses PRMT5 and SOS1 programs to Kaveri Therapeutics for $1.6M in equity, a tiny bet against a ₹1,07,152 cr market cap.
Bajaj Healthcare Q1 revenue up 11%; results reiterate known numbers
Domestic API sales jumped 27% but exports slipped. The press release adds nothing new beyond the board outcome.
Bajaj Healthcare logs 11% revenue growth in Q1, PBT up 13%
Standalone revenue from continuing operations rose to ₹165.63 crore in the June 2026 quarter; board also approved continuation of independent director beyond age 75.
Venus Remedies Q1 net profit more than doubles to ₹25.53 cr
Standalone revenue rose 30% to ₹178.80 cr from ₹137.13 cr a year ago. EBITDA jumped to ₹39.11 cr. Board approved technical MoA alteration.
Venus Remedies Q1 profit more than doubles on 30% revenue jump
Revenue rose to ₹178.80 crore and net profit hit ₹25.53 crore from ₹11.70 crore a year ago. Company remains debt-free.
Emcure's semaglutide gets CDSCO nod for fatty liver disease MASH
India's first GLP-1 receptor agonist cleared for non-cirrhotic MASH with moderate to advanced fibrosis. Poviztra adds a major new indication to its existing approvals for weight management, CVD, and adolescent obesity.
Wanbury's Tanuku API plant lands six USFDA observations
Routine cGMP inspection ends with Form 483 citing six observations at the Tanuku facility. Company says it will respond; the same site recently passed a TGA audit.
Aarti Drugs' key amines unit faces GPCB closure order
The Gujarat Pollution Control Board has ordered closure of Aarti's methylamine plant at Saykha within 15 days for water pollution violations, threatening a backward integration project.
Alembic's partner lands tentative OK for $1.4B cancer drug
NATCO's tentative approval for generic Olaparib puts Alembic in position to distribute a blockbuster, pending patent resolution.
Natco gets tentative FDA nod for generic Lynparza; launch hinges on patent case
US FDA clears Natco's olaparib tablets as generic version of AstraZeneca's $1.4B cancer drug, but Paragraph IV litigation keeps commercial launch uncertain.
Cipla's InvaGen unit gets single USFDA observation, no warning letter
A routine cGMP inspection at the New York facility ended with one Form 483 observation. The outcome is minor compared to more severe regulatory actions.
Astonea Labs raises ₹2.99 cr from Gurugram property sale
The nano-cap pharma seller unloaded two commercial units in JMD Megapolis IT Park to the Satija family. At just 1% of market cap, it's a modest cash boost.
Gujarat Themis placed on rating watch; acquisitions cost 10x net worth
CARE flagged that Gujarat Themis's planned acquisitions are ten times its tangible net worth and funding is uncertain. The company protests, but the rating action signals a possible downgrade.
Brooks Labs locks in ₹191 cr floor for retained stake in Steriscience
Binding MoU secures valuation floor, anti-dilution rights, and guarantee relief for the 32.67% holding, nearly matching the company's entire ₹206 cr market cap.
Panacea Biotec gets HC stay on labour award recoveries
The company has now appealed all 4 tribunal awards. The High Court's interim order prevents coercive action on the first 3, reducing immediate enforcement risk.
AstraZeneca India gets CDSCO nod for Fasenra in rare hypereosinophilic syndrome
The approval expands the drug's use beyond severe asthma, but the patient pool for this rare disease is small. Financial impact is likely modest relative to recent oncology wins.
Kobo Biotech's resolution plan misses 10 July deadline, no funds yet
NCLT-approved ₹70.11 crore plan from Beaufond Industries was due within 60 days. As of 14 July, terms remain unfulfilled. Monitoring committee to decide next steps.
EMA clears Biocon's new Semglee fill line in Malaysia
European nod expands capacity for biosimilar insulin glargine at Johor plant; shipments to begin Q2 FY27, financial impact undisclosed.
Hemo Organic's Q1 revenue nil, auditor flags books again
No revenue from operations for the quarter ended June 2026, down from ₹92.70 lakh in the prior quarter. Net loss narrowed to ₹7.42 lakh but the auditor again qualified the opinion citing unverified trade balances.
Wanbury pays off ₹180 cr NCDs five years early
Board approves early redemption in full of 12.5% secured NCDs originally maturing in 2030, wiping out a substantial debt ahead of schedule.
Shilpa Medicare loses biologics CEO at key growth phase
Dr Sridevi Khambhampaty resigns from Shilpa Biologicals effective July 15, citing personal commitments, with no successor named.
Dr. Reddy's semaglutide transcript confirms timeline, write-down coming
July 9 call transcript filed; no new facts but formalises October restart, 6-7 million pen target, and an inventory hit in Q1.
Mylan dumps its 5.64% Biocon stake in ₹4,000 cr open-market sale
Long-term biosimilars partner sells entire 9.19 crore shares in a single day. Exit removes a strategic investor and creates a supply overhang.
Gujarat Inject Q1 net profit rises to ₹1.25 crore on solar trading
Net profit of ₹1.25 crore marks 69% of FY26 full-year profit, driven by a 414% revenue surge from the solar module business. The results were already disclosed in an earlier board filing.
Gujarat Inject Q1 net profit jumps to ₹125.16 lakh on solar trading
Revenue rises five-fold to ₹1,245.45 lakh; strong solar module trading continues. But the nano-cap pharma company faces a leadership void after recent deaths.
Gujarat Inject Q1 net profit jumps to ₹125.16 lakh on solar module trading
Revenue quintupled to ₹1,245.45 lakh as the company delivers on the ₹14.49 cr solar order landed in June. The trajectory was already visible in prior quarters.
Sun Pharma wins SA approval for generic semaglutide, second market after India
The once-weekly injection for type 2 diabetes will launch in coming days, expanding Sun's global semaglutide franchise beyond India.
Zenith Healthcare to absorb Achyut, promoter stake to rise to 45.8%
Nano-cap with ₹7.42 cr net worth merges with ₹35.06 cr entity. Share count jumps from 5.37 cr to 62.81 cr.
Achyut shareholders to swap into Zenith at 119-for-50 ratio
Nano-cap API trader merges into WHO-certified manufacturer. Combined group could streamline operations, but deal awaits NCLT and shareholder approval.
Astonea Labs passes Yemeni drug regulator's facility inspection
Panchkula plant cleared by SBDMA, opening doors for product registration and exports to Yemen, but no orders or revenue disclosed yet.
IOL Chemicals wins China drug nod for blood thinner API
China's NMPA cleared IOL's Clopidogrel Bisulfate API, adding a large market to its European foothold. But a fire and below-target plant utilization temper the near-term outlook.